Celgene (CELG): Reiterate Buy Ahead of Binary Event - Jefferies

August 9, 2016 7:42 AM EDT
Get Alerts CELG Hot Sheet
Price: $111.68 -0.56%

Rating Summary:
    28 Buy, 8 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 18 | Down: 17 | New: 10
Trade CELG Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Jefferies analyst, Brian Abrahams, reiterated his Buy rating on shares of Celgene (NASDAQ: CELG) ahead of GED-0301 data which will provide critical insights into the viability of the program. The analyst believes CELG will provide top-line data from the GED-0301 endoscopy study in Crohn's Aug/Sept and present full data at UEGW or a later 4Q medical mtg. The analyst expects the data to be a "binary" event for the program, as physician consultants note an improvement on the endoscopy score would not only provide more concrete evidence of '0301's activity following strong ph.II symptomatic benefits, but as an endpoint in itself necessary for a new Crohn's drug to be accepted by regulators and providers.

No change to the price target of $137.00.

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Shares of Celgene closed at $113.63 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Add Your Comment